Showing results (71-80 of 105) with videos related to
Sort By:
Pageof 11
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|October 1, 2015
The role of HE4 for prediction of recurrence in epithelial ovarian cancer patients-results from the OVCAD studyMani Nassir, Jun Guan, Hrvoje Luketina, et al.Journal for Immunotherapy of Cancer|January 8, 2025
Safety and efficacy of the therapeutic DNA-based vaccine VB10.16 in combination with atezolizumab in persistent, recurrent or metastatic HPV16-positive cervical cancer: a multicenter, single-arm phase 2a studyPeter Hillemanns, Michal Zikan, Frédéric Forget, et al.Gynecologic Oncology Research and Practice|March 14, 2017
Preference of elderly patients' to oral or intravenous chemotherapy in heavily pre-treated recurrent ovarian cancer: final results of a prospective multicenter trialRadoslav Chekerov, Philipp Harter, Stefan Fuxius, et al.Med (New York, N.Y.)|October 10, 2025
Photodynamic therapy for high-grade squamous intraepithelial lesions: A randomized controlled trialFei Chen, Peter Hillemanns, Hongjie Ruan, et al.Journal of Cancer Research and Clinical Oncology|March 31, 2023
Pazopanib with Topotecan weekly for patients with platinum-resistant or intermediate-sensitive recurrent ovarian cancer: results of a multicentre, open label phase I/II study (TOPAZ)Radoslav Chekerov, Tjadina Arndt, Klaus Pietzner, et al.International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 10, 2025
A randomized, phase III study of sacituzumab govitecan versus treatment of the physician's choice in patients with endometrial cancer after platinum-based chemotherapy and immunotherapy: the ASCENT-GYN-01 study (GOG-3104/ENGOT-en26/APGOT-EN2)Ramez N Eskander, Bradley Corr, David Cibula, et al.Journal of Cancer Research and Clinical Oncology|February 28, 2019
Vascular endothelial growth factor receptor 2 (VEGFR2) correlates with long-term survival in patients with advanced high-grade serous ovarian cancer (HGSOC): a study from the Tumor Bank Ovarian Cancer (TOC) ConsortiumJun Guan, Silvia Darb-Esfahani, Rolf Richter, et al.Gynecologic Oncology|July 21, 2019
Predicting the course of disease in recurrent vulvar cancer - A subset analysis of the AGO-CaRE-1 studyLinn Woelber, Christine Eulenburg, Jens Kosse, et al.Annals of Surgical Oncology|March 16, 2021
Role of Pelvic Lymph Node Resection in Vulvar Squamous Cell Cancer: A Subset Analysis of the AGO-CaRE-1 StudyLinn Woelber, Mareike Bommert, Philipp Harter, et al.Journal of the National Cancer Institute|January 26, 2015
Adjuvant therapy in lymph node-positive vulvar cancer: the AGO-CaRE-1 studySven Mahner, Julia Jueckstock, Felix Hilpert, et al.Pageof 11